FINWIRES · TerminalLIVE
FINWIRES

SHA:600789

6 stories mentioning SHA:600789Updated just now

Every FINWIRES story that references SHA:600789, newest first.

What's the latest news on SHA:600789?

Asia

Lukang Pharma Secures Chinese Drug Regulator's Nod to Register Imatinib Mesylate

Shandong Lukang Pharmaceutical (SHA:600789) obtained drug registration certificates from China's National Medical Products Administration for the active pharmaceutical ingredient, imatinib mesylate, according to a Shanghai bourse filing on Wednesday.The Chinese pharmaceutical company's shares slipped 1% at the close.The API is used for patients with Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia.

SHA:600789
Asia

Lukang Pharma Gets Nod to Market Lenvatinib Mesylate API

Shandong Lukang Pharmaceutical (SHA:600789) received approval from China's National Medical Products Administration for the marketing of lenvatinib mesylate as a chemical active pharmaceutical ingredient, according to a Shanghai bourse filing on Thursday.The drug is used as a treatment for patients with unresectable hepatocellular carcinoma who have not previously received systemic therapy.The Chinese pharmaceutical company's shares rose 2% during the afternoon trade.

SHA:600789
Asia

Shandong Lukang Pharmaceutical Gets China Marketing Approval for Antipsychotic API

Shandong Lukang Pharmaceutical (SHA:600789) received marketing application approval from China's National Medical Products Administration for brexpiprazole as an active pharmaceutical ingredient, according to a Thursday filing with the Shanghai bourse.The ingredient is an antipsychotic that helps balance dopamine and serotonin, according to the filing.Lukang has so far invested nearly 4.8 million yuan in research and development of the drug, it said.Shares rose 2% during afternoon trading on Thursday.

SHA:600789
Asia

Lukang Pharma to Invest 370 Million Yuan in Green Biomanufacturing Project

Shandong Lukang Pharmaceutical (SHA:600789) plans to invest 370.1 million yuan to build a green bio-manufacturing project, according to a Shanghai bourse filing on Thursday.The project includes the construction of production workshops, warehouses, a high-bay warehouse, a control room, a liquid storage tank area, and an office building.

SHA:600789
Asia

Shandong Lukang Pharmaceutical to Invest Nearly 194 Million Yuan in Intelligent API Plant

Shandong Lukang Pharmaceutical (SHA:600789) will invest 193.5 million yuan to build a continuous intelligent manufacturing chemical active pharmaceutical ingredient (API) project at its biomedical industrial park.The 18-month project will include a multi-purpose API workshop, storage facilities and supporting control infrastructure, according to a Thursday filing with the Shanghai bourse.

SHA:600789
Asia

Shandong Lukang Pharmaceutical Wins Pre-Bid for Antibiotic Under China Drug Procurement Program

Shandong Lukang Pharmaceutical's (SHA:600789) vancomycin hydrochloride injection won a preliminary bid under China's drug procurement program, according to a Tuesday disclosure to the Shanghai bourse.The drug is an antibiotic injection indicated for methicillin-resistant Staphylococcus aureus, among other bacteria, the company said in its filing.Shandong Lukang's sales of the antibiotic reached 5.4 million yuan in 2025.

SHA:600789

Track with the FINWIRES app suite

FolioX
FolioX
Track SHA:600789 in your portfolio
WheelAI
WheelAI
Analyze SHA:600789 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on SHA:600789